Effect of steatosis on liver signal and enhancement on multiphasic contrast-enhanced magnetic resonance imaging

Ali Pirasteh; Haley R. Clark; Endel A. Sorra; Ivan Pedrosa; Takeshi Yokoo

doi:10.1007/s00261-016-0736-5

Effect of steatosis on liver signal and enhancement on multiphasic contrast-enhanced magnetic resonance imaging

Ali Pirasteh, Haley R. Clark, Endel A. Sorra, Ivan Pedrosa, Takeshi Yokoo

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Purpose: To investigate the effect of steatosis on liver signal and enhancement in multiphasic contrast-enhanced (MCE) MRI. Materials and methods: In this IRB-approved, HIPAA-compliant, retrospective, observational study, 1217 MCE abdominal MRIs performed during 2014 at a single institution were reviewed. Of these, 1085 were excluded, due to potential factors other than steatosis that may affect liver signal intensity and/or enhancement. In the remaining 132, liver fat fraction (FF) was calculated from the in- and opposed-phase 2D T1-weighted images. Liver signal intensity, absolute enhancement, and relative enhancement on fat-suppressed (Dixon method) 3D T1-weighted images before and after injection of gadobutrol (arterial, portal venous, and equilibrium phases) were plotted against co-localized FF values and the linear trend was evaluated by Pearson correlation coefficient (r). P values

Original language	English (US)
Pages (from-to)	1-7
Number of pages	7
Journal	Abdominal Radiology
DOIs	https://doi.org/10.1007/s00261-016-0736-5
State	Accepted/In press - Apr 23 2016

Keywords

Contrast media
Fatty liver
Gadolinium
Liver steatosis
Magnetic resonance imaging

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Gastroenterology
Urology
Radiological and Ultrasound Technology

Access to Document

10.1007/s00261-016-0736-5

Cite this

@article{2640d623e066418d93da06f5353b58e9,

title = "Effect of steatosis on liver signal and enhancement on multiphasic contrast-enhanced magnetic resonance imaging",

abstract = "Purpose: To investigate the effect of steatosis on liver signal and enhancement in multiphasic contrast-enhanced (MCE) MRI. Materials and methods: In this IRB-approved, HIPAA-compliant, retrospective, observational study, 1217 MCE abdominal MRIs performed during 2014 at a single institution were reviewed. Of these, 1085 were excluded, due to potential factors other than steatosis that may affect liver signal intensity and/or enhancement. In the remaining 132, liver fat fraction (FF) was calculated from the in- and opposed-phase 2D T1-weighted images. Liver signal intensity, absolute enhancement, and relative enhancement on fat-suppressed (Dixon method) 3D T1-weighted images before and after injection of gadobutrol (arterial, portal venous, and equilibrium phases) were plotted against co-localized FF values and the linear trend was evaluated by Pearson correlation coefficient (r). P values ",

keywords = "Contrast media, Fatty liver, Gadolinium, Liver steatosis, Magnetic resonance imaging",

author = "Ali Pirasteh and Clark, {Haley R.} and Sorra, {Endel A.} and Ivan Pedrosa and Takeshi Yokoo",

year = "2016",

month = apr,

day = "23",

doi = "10.1007/s00261-016-0736-5",

language = "English (US)",

pages = "1--7",

journal = "Abdominal Radiology",

issn = "2366-004X",

publisher = "Springer New York",

}

TY - JOUR

T1 - Effect of steatosis on liver signal and enhancement on multiphasic contrast-enhanced magnetic resonance imaging

AU - Pirasteh, Ali

AU - Clark, Haley R.

AU - Sorra, Endel A.

AU - Pedrosa, Ivan

AU - Yokoo, Takeshi

PY - 2016/4/23

Y1 - 2016/4/23

N2 - Purpose: To investigate the effect of steatosis on liver signal and enhancement in multiphasic contrast-enhanced (MCE) MRI. Materials and methods: In this IRB-approved, HIPAA-compliant, retrospective, observational study, 1217 MCE abdominal MRIs performed during 2014 at a single institution were reviewed. Of these, 1085 were excluded, due to potential factors other than steatosis that may affect liver signal intensity and/or enhancement. In the remaining 132, liver fat fraction (FF) was calculated from the in- and opposed-phase 2D T1-weighted images. Liver signal intensity, absolute enhancement, and relative enhancement on fat-suppressed (Dixon method) 3D T1-weighted images before and after injection of gadobutrol (arterial, portal venous, and equilibrium phases) were plotted against co-localized FF values and the linear trend was evaluated by Pearson correlation coefficient (r). P values

AB - Purpose: To investigate the effect of steatosis on liver signal and enhancement in multiphasic contrast-enhanced (MCE) MRI. Materials and methods: In this IRB-approved, HIPAA-compliant, retrospective, observational study, 1217 MCE abdominal MRIs performed during 2014 at a single institution were reviewed. Of these, 1085 were excluded, due to potential factors other than steatosis that may affect liver signal intensity and/or enhancement. In the remaining 132, liver fat fraction (FF) was calculated from the in- and opposed-phase 2D T1-weighted images. Liver signal intensity, absolute enhancement, and relative enhancement on fat-suppressed (Dixon method) 3D T1-weighted images before and after injection of gadobutrol (arterial, portal venous, and equilibrium phases) were plotted against co-localized FF values and the linear trend was evaluated by Pearson correlation coefficient (r). P values

KW - Contrast media

KW - Fatty liver

KW - Gadolinium

KW - Liver steatosis

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=84964240986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964240986&partnerID=8YFLogxK

U2 - 10.1007/s00261-016-0736-5

DO - 10.1007/s00261-016-0736-5

M3 - Article

C2 - 27108126

AN - SCOPUS:84964240986

SN - 2366-004X

SP - 1

EP - 7

JO - Abdominal Radiology

JF - Abdominal Radiology

ER -

Effect of steatosis on liver signal and enhancement on multiphasic contrast-enhanced magnetic resonance imaging

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this